HRP20100373T4 - Upotreba kombinacije morfina s najmanje jednim opijatnim antagonistom u liječenju ovisnosti o opijatima i u sprječavanju neoralne zloupotrebe opijata kod ovisnika opijatima - Google Patents
Upotreba kombinacije morfina s najmanje jednim opijatnim antagonistom u liječenju ovisnosti o opijatima i u sprječavanju neoralne zloupotrebe opijata kod ovisnika opijatima Download PDFInfo
- Publication number
- HRP20100373T4 HRP20100373T4 HRP20100373TT HRP20100373T HRP20100373T4 HR P20100373 T4 HRP20100373 T4 HR P20100373T4 HR P20100373T T HRP20100373T T HR P20100373TT HR P20100373 T HRP20100373 T HR P20100373T HR P20100373 T4 HRP20100373 T4 HR P20100373T4
- Authority
- HR
- Croatia
- Prior art keywords
- morphine
- opiate
- delayed
- use according
- naloxone
- Prior art date
Links
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 title claims abstract 28
- 229960005181 morphine Drugs 0.000 title claims abstract 14
- 239000003401 opiate antagonist Substances 0.000 title claims abstract 8
- 229940127240 opiate Drugs 0.000 title claims abstract 5
- 208000026251 Opioid-Related disease Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000003111 delayed effect Effects 0.000 claims abstract 13
- 230000000694 effects Effects 0.000 claims abstract 3
- 229960004127 naloxone Drugs 0.000 claims 7
- RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical group Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- TXMZWEASFRBVKY-IOQDSZRYSA-N (4r,4as,7ar,12bs)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;dihydrate;hydrochloride Chemical compound O.O.Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C TXMZWEASFRBVKY-IOQDSZRYSA-N 0.000 claims 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 2
- 229960002069 diamorphine Drugs 0.000 claims 2
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 claims 2
- 229960004088 naloxone hydrochloride dihydrate Drugs 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 238000009256 replacement therapy Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960005195 morphine hydrochloride Drugs 0.000 claims 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 claims 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Upotreba nerazdvojive kombinacije morfina ili njegovih fiziološki prihvatljivih soli i najmanje jednog opijatnog antagonista ili njegovih fiziološki prihvatljivih soli, s bioraspoloživosti manjom od 5%, u oralnoj primjeni, naznačena time što je kombinacija namijenjena proizvodnji lijeka namijenjenog samo za oralnu primijenu kao zamjenske terapije kod ovisnika o opijatima ili ovisnika o heroinu, gdje je opioidni antagonist nalokson.
2. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što lijek također smanjuje ili sprječava nuspojave specifične za opijate.
3. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je morfin odgođen i najmanje jedan opijatni antagonist je odgođeni, morfin je odgođen, a najmanje jedan opijatni antagonist je neodgođen, morfin je neodgođen, a najmanje jedan opijatni antagonist je odgođen, morfin je neodgođeni i najmanje jedan opijatni antagonist je neodgođen.
4. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time stoje morfin adsorbiran na polimer i uklopljen u matriks, ili stoje morfin suspendiran u etil-celuloznom polimeru.
5. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se zamjensku terapiju upotrebljava kod ovisnika o heroinu.
6. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što pripravak treba uzimati ili primijeniti jednom ili dva puta dnevno.
7. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se morfin upotrebljava u obliku morfin-hidroklorida ili pentahidrata morfin-sulfata.
8. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačena time što se nalokson upotrebljava u obliku nalokson-hidroklorida ili dihidrata nalokson-hidroklorida.
9. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što lijek sadrži 100 mg do 2000 mg odgođenog morfina.
10. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačena time što lijek sadrži 0,1 mg do 10 mg naloksona po 100 mg odgođenog morfina.
11. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što su odgođeni morfin i neodgođeni nalokson prisutni u obliku granulirane smjese, gdje je veličina zrna granula po mogućnosti između od 0,1 mm i 2 mm.
12. Upotreba u skladu s prethodnim patentnim zahtjevom, naznačena time što je morfin pentahidrat morfin-sulfata, a nalokson je nalokson-hidroklorid ili dihidrat nalokson-hidroklorida.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06100578A EP1810678A1 (de) | 2006-01-19 | 2006-01-19 | Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution |
| EP07704010.3A EP1976524B2 (de) | 2006-01-19 | 2007-01-19 | Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen |
| PCT/EP2007/050540 WO2007082935A1 (de) | 2006-01-19 | 2007-01-19 | Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20100373T1 HRP20100373T1 (hr) | 2010-08-31 |
| HRP20100373T4 true HRP20100373T4 (hr) | 2016-12-16 |
Family
ID=36675685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20100373TT HRP20100373T4 (hr) | 2006-01-19 | 2010-07-05 | Upotreba kombinacije morfina s najmanje jednim opijatnim antagonistom u liječenju ovisnosti o opijatima i u sprječavanju neoralne zloupotrebe opijata kod ovisnika opijatima |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20100221339A1 (hr) |
| EP (2) | EP1810678A1 (hr) |
| CN (2) | CN103893179A (hr) |
| AT (1) | ATE465735T1 (hr) |
| AU (1) | AU2007206914B2 (hr) |
| CA (1) | CA2637458C (hr) |
| CY (1) | CY1110152T1 (hr) |
| DE (1) | DE502007003589D1 (hr) |
| DK (1) | DK1976524T4 (hr) |
| EA (1) | EA014539B1 (hr) |
| ES (1) | ES2345286T5 (hr) |
| HK (1) | HK1198744A1 (hr) |
| HR (1) | HRP20100373T4 (hr) |
| PL (1) | PL1976524T5 (hr) |
| PT (1) | PT1976524E (hr) |
| RS (1) | RS51388B2 (hr) |
| SI (1) | SI1976524T1 (hr) |
| UA (1) | UA92380C2 (hr) |
| WO (1) | WO2007082935A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007024428A1 (de) | 2007-05-25 | 2008-11-27 | Hermann, Holger Lars, Dr. med. | Verwendung von Naloxon als Abususschutz bei Nicht-Opioiden und Nicht-Opiaten |
| EP2421515A2 (de) | 2009-04-22 | 2012-02-29 | Lars Holger Hermann | Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten |
| JP2012087101A (ja) | 2010-10-21 | 2012-05-10 | Holger Hermann Lars | オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物 |
| CN103695497B (zh) * | 2013-12-20 | 2014-09-17 | 奇方(天津)医药科技有限公司 | 纳洛酮的酶法制备及其药物组合物 |
| EP3082816B1 (en) | 2013-12-20 | 2019-03-20 | Indivior UK Limited | Intranasal naloxone compositions and methods of making and using same |
| WO2015089530A1 (de) | 2013-12-20 | 2015-06-25 | G.L. PHARMA GmbH | Orale darreichungsform mit verzögerter freisetzung enthaltend morphin und naloxon |
| US20160256451A1 (en) * | 2015-03-06 | 2016-09-08 | Develco Pharma Schweiz Ag | Dosage of naloxone |
| WO2016193456A2 (en) * | 2015-06-03 | 2016-12-08 | Develco Pharma Schweiz Ag | Opioid receptor antagonist for use in treating patients with severe constipation |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1390772A (en) * | 1971-05-07 | 1975-04-16 | Endo Lab | Oral narcotic composition |
| US4769372A (en) * | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US5580876A (en) † | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| SE9301057L (sv) | 1993-03-30 | 1994-10-01 | Pharmacia Ab | Beredning med kontrollerad frisättning |
| DE4325465B4 (de) * | 1993-07-29 | 2004-03-04 | Zenz, Michael, Prof. Dr.med. | Orales pharmazeutisches Präparat für die Schmerztherapie |
| AT403988B (de) | 1994-05-18 | 1998-07-27 | Lannacher Heilmittel | Festes orales retardpräparat |
| US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| ATE211906T1 (de) * | 1996-03-12 | 2002-02-15 | Alza Corp | Zusammensetzung und dosisform mit einem opioid- antagonisten |
| EP0914823B1 (de) | 1997-11-06 | 2004-12-08 | Lannacher Heilmittel Ges.m.b.H. | Orale Retard-Präparation enthaltend Tramadol sowie Verfahren zu ihrer Herstellung |
| PT1685839E (pt) * | 1997-12-22 | 2013-07-08 | Euro Celtique Sa | Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide |
| KR100417490B1 (ko) * | 1997-12-22 | 2004-02-05 | 유로-셀티크 소시에떼 아노뉨 | 오피오이드 제형의 남용을 방지하는 방법 |
| AU2406299A (en) | 1998-02-12 | 1999-08-30 | Centrapharm Inc. | Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect |
| AU776904B2 (en) * | 2000-02-08 | 2004-09-23 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| DE60238756D1 (de) † | 2001-05-11 | 2011-02-10 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
| US20030044458A1 (en) † | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| DE20308437U1 (de) | 2002-04-05 | 2003-11-13 | Euroceltique S.A., Luxemburg/Luxembourg | Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen |
| EP2422775A3 (en) | 2002-09-20 | 2012-04-18 | Alpharma, Inc. | Sequestering subunit and related compositions and methods |
| US20050191244A1 (en) * | 2002-10-25 | 2005-09-01 | Gruenenthal Gmbh | Abuse-resistant pharmaceutical dosage form |
| US20040110781A1 (en) * | 2002-12-05 | 2004-06-10 | Harmon Troy M. | Pharmaceutical compositions containing indistinguishable drug components |
| AT503858B1 (de) | 2003-06-05 | 2008-08-15 | Lannacher Heilmittel | Verfahren zur herstellung einer festen oralen pharmazeutischen zusammensetzung, enthaltend ein jodsalz |
| EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
| EP1771160A2 (en) | 2005-01-28 | 2007-04-11 | Euroceltique S.A. | Alcohol resistant dosage forms |
| FR2889810A1 (fr) * | 2005-05-24 | 2007-02-23 | Flamel Technologies Sa | Forme medicamenteuse orale, microparticulaire, anti-mesurage |
| GB2471801B (en) | 2006-05-25 | 2011-02-16 | Alpharma | Process useful in the preparation of morphine antagonists |
| SI2484346T1 (sl) | 2006-06-19 | 2017-05-31 | Alpharma Pharmaceuticals Llc | Farmacevtski sestavki |
-
2006
- 2006-01-19 EP EP06100578A patent/EP1810678A1/de not_active Withdrawn
-
2007
- 2007-01-19 AT AT07704010T patent/ATE465735T1/de active
- 2007-01-19 US US12/161,397 patent/US20100221339A1/en not_active Abandoned
- 2007-01-19 ES ES07704010.3T patent/ES2345286T5/es active Active
- 2007-01-19 AU AU2007206914A patent/AU2007206914B2/en not_active Ceased
- 2007-01-19 UA UAA200810463A patent/UA92380C2/ru unknown
- 2007-01-19 PT PT07704010T patent/PT1976524E/pt unknown
- 2007-01-19 EA EA200870182A patent/EA014539B1/ru unknown
- 2007-01-19 EP EP07704010.3A patent/EP1976524B2/de active Active
- 2007-01-19 PL PL07704010T patent/PL1976524T5/pl unknown
- 2007-01-19 RS RS20100341A patent/RS51388B2/sr unknown
- 2007-01-19 DE DE502007003589T patent/DE502007003589D1/de active Active
- 2007-01-19 DK DK07704010.3T patent/DK1976524T4/en active
- 2007-01-19 CA CA2637458A patent/CA2637458C/en active Active
- 2007-01-19 WO PCT/EP2007/050540 patent/WO2007082935A1/de active Application Filing
- 2007-01-19 CN CN201410124301.5A patent/CN103893179A/zh active Pending
- 2007-01-19 SI SI200730285T patent/SI1976524T1/sl unknown
- 2007-01-19 CN CNA2007800026334A patent/CN101370503A/zh active Pending
-
2010
- 2010-06-24 CY CY20101100578T patent/CY1110152T1/el unknown
- 2010-07-05 HR HRP20100373TT patent/HRP20100373T4/hr unknown
-
2014
- 2014-12-04 HK HK14112247.0A patent/HK1198744A1/xx unknown
-
2016
- 2016-06-20 US US15/187,374 patent/US10507205B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10507205B2 (en) | 2019-12-17 |
| AU2007206914B2 (en) | 2012-08-23 |
| EP1810678A1 (de) | 2007-07-25 |
| UA92380C2 (ru) | 2010-10-25 |
| RS51388B2 (sr) | 2018-02-28 |
| SI1976524T1 (sl) | 2010-08-31 |
| ATE465735T1 (de) | 2010-05-15 |
| EA200870182A1 (ru) | 2009-02-27 |
| DE502007003589D1 (de) | 2010-06-10 |
| US20100221339A1 (en) | 2010-09-02 |
| ES2345286T5 (es) | 2017-04-25 |
| HRP20100373T1 (hr) | 2010-08-31 |
| CA2637458A1 (en) | 2007-07-26 |
| HK1198744A1 (en) | 2015-06-05 |
| EA014539B1 (ru) | 2010-12-30 |
| CN101370503A (zh) | 2009-02-18 |
| PT1976524E (pt) | 2010-07-05 |
| ES2345286T3 (es) | 2010-09-20 |
| EP1976524B1 (de) | 2010-04-28 |
| RS51388B (en) | 2011-02-28 |
| US20170136005A1 (en) | 2017-05-18 |
| DK1976524T4 (en) | 2016-12-05 |
| EP1976524A1 (de) | 2008-10-08 |
| CY1110152T1 (el) | 2015-01-14 |
| AU2007206914A1 (en) | 2007-07-26 |
| CN103893179A (zh) | 2014-07-02 |
| EP1976524B2 (de) | 2016-08-10 |
| WO2007082935A1 (de) | 2007-07-26 |
| PL1976524T5 (pl) | 2017-12-29 |
| DK1976524T3 (da) | 2010-08-09 |
| CA2637458C (en) | 2015-03-10 |
| PL1976524T3 (pl) | 2010-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100373T4 (hr) | Upotreba kombinacije morfina s najmanje jednim opijatnim antagonistom u liječenju ovisnosti o opijatima i u sprječavanju neoralne zloupotrebe opijata kod ovisnika opijatima | |
| CA2235375C (en) | Production of analgesic synergy by co-administration of sub-analgesic doses of a .mu. opioid agonist and a .kappa.-2 opioid agonist | |
| EP2964022B1 (en) | Pain medicine combination and uses thereof | |
| UA93543C2 (ru) | Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон | |
| JP2009143964A5 (hr) | ||
| HRP20110049T2 (hr) | Opioidi za liječenje nemirnosti kod donjih ekstremiteta | |
| EP2283843A3 (en) | Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) | |
| IL221795B (en) | Use of a pharmaceutical preparation of methylnaltrexone or a salt thereof for the preparation of a medicine for the treatment of side effects of treatment with opiates | |
| RU2011104146A (ru) | Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи | |
| UA86621C2 (ru) | Антагонисты рецептора глюкагона, их получение и терапевтическое применение | |
| RU2007149044A (ru) | Твердые лекарственные формы наркотических лекарственных средств с улучшенным всасыванием при трансбуккальном введении | |
| JP2011137020A5 (hr) | ||
| WO2007031887A3 (en) | Extended release pharmaceutical composition of metformin and a process for producing it | |
| RU2013136350A (ru) | Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист | |
| EA200870449A1 (ru) | Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами | |
| WO2008067399A3 (en) | Controlled-release multi-layer formulation of piperazine-piperidine antagonists and agonists of the 5-th1a receptor having enhanced intestinal dissolution | |
| PT2205279E (pt) | Associação farmacêutica de aliscireno e valsartan | |
| TNSN07474A1 (en) | Dosage regimen for prasugrel | |
| SK287180B6 (sk) | Kombinácia účinných látok na medikamentóznu terapiu návykových alebo omamných prostriedkov | |
| WO2007145863A3 (en) | Sustained release formulation of naltrexone | |
| JP2007197423A5 (hr) | ||
| JP7244992B2 (ja) | オピオイドとｎ－アシルエタノールアミンの組み合わせ | |
| JP2009526833A5 (hr) | ||
| US11779581B2 (en) | Opioid for use to reduce and/or treat drug addiction | |
| JP2004522780A5 (hr) |